Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?

Detalles Bibliográficos
Autores principales: Li, Ying, Shen, Lin, Yin, Xudong, Chen, Zixuan, Chen, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562903/
https://www.ncbi.nlm.nih.gov/pubmed/37822732
http://dx.doi.org/10.1016/j.lanwpc.2023.100926
_version_ 1785118231769382912
author Li, Ying
Shen, Lin
Yin, Xudong
Chen, Zixuan
Chen, Yong
author_facet Li, Ying
Shen, Lin
Yin, Xudong
Chen, Zixuan
Chen, Yong
author_sort Li, Ying
collection PubMed
description
format Online
Article
Text
id pubmed-10562903
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105629032023-10-11 Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer? Li, Ying Shen, Lin Yin, Xudong Chen, Zixuan Chen, Yong Lancet Reg Health West Pac Correspondence Elsevier 2023-10-02 /pmc/articles/PMC10562903/ /pubmed/37822732 http://dx.doi.org/10.1016/j.lanwpc.2023.100926 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Correspondence
Li, Ying
Shen, Lin
Yin, Xudong
Chen, Zixuan
Chen, Yong
Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
title Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
title_full Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
title_fullStr Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
title_full_unstemmed Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
title_short Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
title_sort does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562903/
https://www.ncbi.nlm.nih.gov/pubmed/37822732
http://dx.doi.org/10.1016/j.lanwpc.2023.100926
work_keys_str_mv AT liying doesnivolumabcombinedwithfluorouracilbasedchemotherapyproducehigherobjectiveresponseratethanotherimmunochemotherapyregimesinmetastaticesophagealcancer
AT shenlin doesnivolumabcombinedwithfluorouracilbasedchemotherapyproducehigherobjectiveresponseratethanotherimmunochemotherapyregimesinmetastaticesophagealcancer
AT yinxudong doesnivolumabcombinedwithfluorouracilbasedchemotherapyproducehigherobjectiveresponseratethanotherimmunochemotherapyregimesinmetastaticesophagealcancer
AT chenzixuan doesnivolumabcombinedwithfluorouracilbasedchemotherapyproducehigherobjectiveresponseratethanotherimmunochemotherapyregimesinmetastaticesophagealcancer
AT chenyong doesnivolumabcombinedwithfluorouracilbasedchemotherapyproducehigherobjectiveresponseratethanotherimmunochemotherapyregimesinmetastaticesophagealcancer

Ejemplares similares